Global Pulmonary Arterial Hypertension (PAH) Medicine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pulmonary Arterial Hypertension (PAH) Medicine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Pulmonary Arterial Hypertension (PAH) Medicine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pulmonary Arterial Hypertension (PAH) Medicine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Secondary Pulmonary Hypertension (SPH) and Primary Pulmonary Hypertension (PPH) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pulmonary Arterial Hypertension (PAH) Medicine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pulmonary Arterial Hypertension (PAH) Medicine key manufacturers include Pfizer, Gilead Sciences, Eli Lilly, Actelion Pharmaceuticals and United Therapeutics Corporation, etc. Pfizer, Gilead Sciences, Eli Lilly are top 3 players and held % sales share in total in 2022.
Pulmonary Arterial Hypertension (PAH) Medicine can be divided into Calcium Channel Blockers, Novel Targeted Drugs and Other,, etc. Calcium Channel Blockers is the mainstream product in the market, accounting for % sales share globally in 2022.
Pulmonary Arterial Hypertension (PAH) Medicine is widely used in various fields, such as Secondary Pulmonary Hypertension (SPH) and Primary Pulmonary Hypertension (PPH), etc. Secondary Pulmonary Hypertension (SPH) provides greatest supports to the Pulmonary Arterial Hypertension (PAH) Medicine industry development. In 2022, global % sales of Pulmonary Arterial Hypertension (PAH) Medicine went into Secondary Pulmonary Hypertension (SPH) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pulmonary Arterial Hypertension (PAH) Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
Gilead Sciences
Eli Lilly
Actelion Pharmaceuticals
United Therapeutics Corporation
Segment by Type
Calcium Channel Blockers
Novel Targeted Drugs
Other
Secondary Pulmonary Hypertension (SPH)
Primary Pulmonary Hypertension (PPH)
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Pulmonary Arterial Hypertension (PAH) Medicine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pulmonary Arterial Hypertension (PAH) Medicine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pulmonary Arterial Hypertension (PAH) Medicine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Pulmonary Arterial Hypertension (PAH) Medicine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pulmonary Arterial Hypertension (PAH) Medicine introduction, etc. Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Pulmonary Arterial Hypertension (PAH) Medicine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Pulmonary Arterial Hypertension (PAH) Medicine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pulmonary Arterial Hypertension (PAH) Medicine key manufacturers include Pfizer, Gilead Sciences, Eli Lilly, Actelion Pharmaceuticals and United Therapeutics Corporation, etc. Pfizer, Gilead Sciences, Eli Lilly are top 3 players and held % sales share in total in 2022.
Pulmonary Arterial Hypertension (PAH) Medicine can be divided into Calcium Channel Blockers, Novel Targeted Drugs and Other,, etc. Calcium Channel Blockers is the mainstream product in the market, accounting for % sales share globally in 2022.
Pulmonary Arterial Hypertension (PAH) Medicine is widely used in various fields, such as Secondary Pulmonary Hypertension (SPH) and Primary Pulmonary Hypertension (PPH), etc. Secondary Pulmonary Hypertension (SPH) provides greatest supports to the Pulmonary Arterial Hypertension (PAH) Medicine industry development. In 2022, global % sales of Pulmonary Arterial Hypertension (PAH) Medicine went into Secondary Pulmonary Hypertension (SPH) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pulmonary Arterial Hypertension (PAH) Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
Gilead Sciences
Eli Lilly
Actelion Pharmaceuticals
United Therapeutics Corporation
Segment by Type
Calcium Channel Blockers
Novel Targeted Drugs
Other
Segment by Application
Secondary Pulmonary Hypertension (SPH)
Primary Pulmonary Hypertension (PPH)
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Pulmonary Arterial Hypertension (PAH) Medicine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pulmonary Arterial Hypertension (PAH) Medicine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pulmonary Arterial Hypertension (PAH) Medicine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Pulmonary Arterial Hypertension (PAH) Medicine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pulmonary Arterial Hypertension (PAH) Medicine introduction, etc. Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Pulmonary Arterial Hypertension (PAH) Medicine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices